Gotham Therapeutics, a NYC-based biotechnology company developing a novel drug class targeting RNA-modifying proteins, raised $54m in Series A financing.
The round was co-led by founding investor Versant Ventures, Forbion and S.R. One, with participation from Celgene and Alexandria Venture Investments. In conjunction with the funding, Holger Reithinger, Ph.D., General Partner at Forbion, will join Gotham’s Board of Directors. Jorge DiMartino M.D., Ph.D., Vice President, Translational Development Oncology at Celgene and Head of Celgene’s Epigenetics Thematic Center of Excellence, has joined the board in an observer role.
The company intends to use the funds to establish clinical proof of concept and to invest in a pipeline of preclinical candidates that have potential to treat diseases intractable to classical approaches.
Led by Lee Babiss, Ph.D., CEO, Gotham Therapeutics aims to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, the company plans to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases.
Gotham has a subsidiary near Munich, Germany.